Fig. 7. Atractylodin decreases lipogenic gene expression by activating AMPK. (A-C) qRT-PCR analyses of mRNA levels for lipogenic genes (SREBF1, FASN, and ACACA). HepG2 cells were treated with atractylodin for 1 h followed by T090 treatment for 12 h (n=4). (D) qRT-PCR analysis of SREBF1 mRNA levels. HepG2 cells were treated with 5 μM Compound C (C.C.) for 30 min, followed by 20 μM atractylodin for 1 h, and then 3 μM T090 treatment for 12 h (n=5). (E) Representative western blots for precursor and mature SREBP-1c expression. The precursor form of SREBP-1c was assessed using whole cell lysates (WCL) (upper panel), while the mature form was determined from nuclear fractions (NF) (lower panel). Data are presented as mean ± SEM. Statistical analysis was performed using one-way ANOVA with Tukey’s post-hoc test. **p<0.01: compared with Control (Con); #p<0.05, ##p<0.01: compared with T090 treatment, N.S., not significant.
© Biomolecules & Therapeutics
